Good news! Dr. Dai Hongjiu, the CEO of KAEDI, has been selected as the innovative entrepreneurs in Nanjing's Zijinshan Talent Program.
The talent working group in Nanjing recently released the results of the selection for the Zijinshan Talent Program Innovative Entrepreneur Project , and Dr. Dai Hongjiu was chosen as one of the talents for this program.
Nanjing is focusing on building an innovative city during its new development stage and aims to create a large-scale, well-structured, and high-quality talent pool. The Zijinshan Talent Program Innovative Entrepreneur Project aims to select entrepreneurs who possess both scientific and market knowledge, strong business management skills, and integration capabilities for innovation resources.
These entrepreneurs will play a leading role in guiding and demonstrating high-quality development throughout the city. The election of Dr. Dai Hongjiu in Nanjing's Zijinshan Talent Program Innovative Entrepreneur Project not only recognizes his entrepreneurial spirit and abilities but also serves as encouragement for KAEDI Biotherapeutics’ innovative development. In the future, driven by this recognition, KAEDI will continuously enhance its research and development innovation level along with industry influence.
We will accelerate clinical translation while safeguarding the health of numerous cancer patients. Moreover, we aim to inject new vitality into Jiangbei New District in Nanjing through sustained development efforts.
About KAEDI
KAEDI is a new drug research and development company in the clinical stage that uses leading synthetic biology technologies to develop novel cell therapy drugs for the clinically unmet needs of patients with solid tumors. Relying on its advanced synthetic biology technology platform-KD-SmCAR™, and the dual targeting CAR development platform-KD-ScCAR™. KAEDI has successfully developed a number of first-in-class cell therapy drug development pipelines for malignant solid tumors, including next-generation autologous and allogeneic CAR-T/CAR-NK cell therapy pipelines. At present, KAEDI has been declared more than 30 CAR-related patents in CN and US, and 16 patents have been authorized, among which the core pipeline KD-025 and KD-496 patents are the first authorized in CN and US.
The pre-clinical research results of KD-025 CAR-T targeting NKG2DL for Hepatocellular carcinoma, Medulloblastoma and GBM have been successively published in the international authoritative Journal of tumor immunotherapy such as “Journal for ImmunoTherapy of Cancer” and “Cancer Immunology”. At the same time, the research results were presented at the American Oncology Clinical Annual Meeting ASCO. At present, KD-025 CAR-T IIT clinical trials are being carried out in well-known clinical centers in China, and many cases have been completed, with no obvious toxic and adverse reactions, and the product is safe and effective. The first domestic CAR-T (KD-025 cell injection) targeting NKG2DL for the treatment of solid tumors IND declaration was approved. At present, KAEDI is negotiating with a number of partners to start KD-025 registration phase I clinical trial. In addition, the company's core product which is the world's first new dual-targeted CAR-T (KD-496) cell injection, has successfully entered the clinical stage of IIT, and has completed the first clinical patient administration of pancreatic cancer.
At the same time, the company is advancing the development of the next generation of general-purpose CAR cell drugs, which is expected to develop KAEDI into a global leader in cell drugs in the near future.
KAEDI is headquartered in Nanjing, China. For more information, please visit Nanjing KAEDI Biotherapeutics Co., Ltd. official website:
English website: http://www.kaedibio.com
Chinese website: http://www.kaedibio.com/china/
Collaboration Email: business@kaedibio.com
Clinical Email: clinical.trial@kaedibio.com
Nanjing is focusing on building an innovative city during its new development stage and aims to create a large-scale, well-structured, and high-quality talent pool. The Zijinshan Talent Program Innovative Entrepreneur Project aims to select entrepreneurs who possess both scientific and market knowledge, strong business management skills, and integration capabilities for innovation resources.
These entrepreneurs will play a leading role in guiding and demonstrating high-quality development throughout the city. The election of Dr. Dai Hongjiu in Nanjing's Zijinshan Talent Program Innovative Entrepreneur Project not only recognizes his entrepreneurial spirit and abilities but also serves as encouragement for KAEDI Biotherapeutics’ innovative development. In the future, driven by this recognition, KAEDI will continuously enhance its research and development innovation level along with industry influence.
We will accelerate clinical translation while safeguarding the health of numerous cancer patients. Moreover, we aim to inject new vitality into Jiangbei New District in Nanjing through sustained development efforts.
About KAEDI
KAEDI is a new drug research and development company in the clinical stage that uses leading synthetic biology technologies to develop novel cell therapy drugs for the clinically unmet needs of patients with solid tumors. Relying on its advanced synthetic biology technology platform-KD-SmCAR™, and the dual targeting CAR development platform-KD-ScCAR™. KAEDI has successfully developed a number of first-in-class cell therapy drug development pipelines for malignant solid tumors, including next-generation autologous and allogeneic CAR-T/CAR-NK cell therapy pipelines. At present, KAEDI has been declared more than 30 CAR-related patents in CN and US, and 16 patents have been authorized, among which the core pipeline KD-025 and KD-496 patents are the first authorized in CN and US.
The pre-clinical research results of KD-025 CAR-T targeting NKG2DL for Hepatocellular carcinoma, Medulloblastoma and GBM have been successively published in the international authoritative Journal of tumor immunotherapy such as “Journal for ImmunoTherapy of Cancer” and “Cancer Immunology”. At the same time, the research results were presented at the American Oncology Clinical Annual Meeting ASCO. At present, KD-025 CAR-T IIT clinical trials are being carried out in well-known clinical centers in China, and many cases have been completed, with no obvious toxic and adverse reactions, and the product is safe and effective. The first domestic CAR-T (KD-025 cell injection) targeting NKG2DL for the treatment of solid tumors IND declaration was approved. At present, KAEDI is negotiating with a number of partners to start KD-025 registration phase I clinical trial. In addition, the company's core product which is the world's first new dual-targeted CAR-T (KD-496) cell injection, has successfully entered the clinical stage of IIT, and has completed the first clinical patient administration of pancreatic cancer.
At the same time, the company is advancing the development of the next generation of general-purpose CAR cell drugs, which is expected to develop KAEDI into a global leader in cell drugs in the near future.
KAEDI is headquartered in Nanjing, China. For more information, please visit Nanjing KAEDI Biotherapeutics Co., Ltd. official website:
English website: http://www.kaedibio.com
Chinese website: http://www.kaedibio.com/china/
Collaboration Email: business@kaedibio.com
Clinical Email: clinical.trial@kaedibio.com